Navtemadlin
As of the edition of 20 October 2026, Navtemadlin is a small molecule: in active development; acts on MDM2 and TP53.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 23, 5 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Lungs and airways; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 4 | 2 | 2 |
| Phase 2 | 12 | 0 | 2 | 3 |
| Phase 3 | 3 | 0 | 2 | 0 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Kartos Therapeutics | Lead sponsor of trials | 2012 to now |
| Telios Pharma | Lead sponsor of trials | 2016 to now |